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2808Intriguing Off-Target
Effects of EzetimibeTsujita et al. (1) report patients randomized to ator-
vastatin þ ezetimibe therapy experienced a greater
reduction in the percentage of atheroma volume than
those randomized to atorvastatin, and it may be due
to the lower mean low-density lipoprotein choles-
terol achieved. However, Crea and Niccoli (2) argued
and hypothesized that cholesterol lowering itself
does not seem to explain the greater reduction in the
percentage of atheroma volume with convincing and
intriguing pleiotropic effects of ezetimibe.
Statins are very important to prevent cardiovascular
events in patients at high risk, but dose-dependently
worsen insulin sensitivity and increase the risk of
type 2 diabetes (3). In addition to lowering LDL
cholesterol further, ezetimibe reduced visceral fat
with beneﬁcial effects on adiponectin and insulin
resistance. Indeed, experimental studies demon-
strated that ezetimibe improves liver steatosis and
insulin sensitivity in a rat model of metabolic syn-
drome. We observed that ezetimibe combined with
simvastatin signiﬁcantly decreased insulin levels and
increased adiponectin levels and insulin sensitivity
and reduced visceral fat and blood pressure quite
differently from simvastatin alone in patients with
hypercholesterolemia (4). Indeed, a randomized clin-
ical trial demonstrated that simvastatin combined
with ezetimibe therapy wasmore beneﬁcial in patients
with diabetes than in patients without diabetes
(p interaction ¼ 0.023) (5). These may in part explain
the results of the IMPROVE-IT (Examining Outcomes
in Subjects with Acute Coronary Syndrome: Vytorin
(Ezetimibe/Simvastatin) Versus Simvastatin (P04103)
and PRECISE-IVUS (Plaque Regression With Choles-
terol Absorption Inhibitor or Synthesis Inhibitor Eval-
uated by Intravascular Ultrasound) studies.*Kwang Kon Koh, MD, PhD
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Effects of EzetimibeWe read with great interest the letter by Dr. Koh
commenting on our recent paper (1), and we appre-
ciate his valuable comments on the possible mecha-
nisms underlying the greater coronary plaque
regression observed in patients treated with the
combination of a statin plus ezetimibe compared with
statin monotherapy. In terms of “pleiotropic” bene-
ﬁcial effects of the dual lipid-lowering pharmaco-
therapy, we completely agree with Dr. Koh. As shown
in the Central Illustration demonstrating the rela-
tionship between the achieved low-density lipopro-
tein cholesterol (LDL-C) levels and the median change
in the percentage of atheroma volume (1), the plot
was located far below the pre-existing regression line
in the atorvastatin/ezetimibe combination arm of the
acute coronary syndrome cohort of the PRECISE-IVUS
(Plaque Regression With Cholesterol Absorption In-
hibitor or Synthesis Inhibitor Evaluated by Intravas-
cular Ultrasound) trial, suggesting the presence of
“beyond LDL-C-lowering effect” of the dual lipid
lowering.
What would be the possible explanation of the
“beyond LDL-C?” Looking at Figure 4 in our PRECISE-
IVUS paper (1), coronary plaque regression was
correlated with serum levels of a cholesterol absorp-
tion marker as well as or stronger than with LDL-C.
Also, Dr. Koh mentioned that statin combined with
ezetimibe therapy was more beneﬁcial in patients
with diabetes than without diabetes. Recently, small
dense LDL-C has been highlighted as a new risk factor
for coronary heart disease, and an increased small
dense LDL-C level was found in patients with type 2
diabetes (2). Furthermore, it has been reported
that elevation of small dense LDL-C levels was
associated with insulin resistance (3) and metabolic
